Gift Cards Take Center Stage This Christmas: Australian Shoppers to Spend Nearly Half of Gift Budget on Flexible Presents
MELBOURNE, Australia, Dec. 9, 2024 /PRNewswire/ -- According to new research[1] from global branded payment provider, Blackhawk Network (BHN), Aussie consumers plan to allocate nearly half (44%) of their total gift spend on gift cards, up from 40%...
Moloco Strengthens Asia Pacific Footprint with Key Leadership Hires
Nopparat Yokubon and Jason Bagg Join Moloco to Drive Regional Growth SINGAPORE, Dec. 9, 2024 /PRNewswire/ -- Moloco, the leader in operational machine learning (ML) and performance advertising, announced the appointments of Nopparat Yokubon, as...
Agoda Celebrates International Mountain Day with Top 5 Mountain Destinations in Asia
SINGAPORE, Dec. 9, 2024 /PRNewswire/ -- In celebration of International Mountain Day on December 11, digital travel platform Agoda shares the top five mountain destinations across Asia based on Agoda's 2024 booking data. These destinations offer...
Globally top 5%, Astronergy won greater-value EcoVadis group scope gold rating
HANGZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Astronergy, full name in Chint New Energy Technology Co.,Ltd., has received a group-level gold medal from EcoVadis, placing the company among the 5% best enterprises evaluated globally in Environment,...
Hipfest 2024: International Hip-hop Culture Festival Explodes In Vietnam
HO CHI MINH CITY, Vietnam, Dec. 9, 2024 /PRNewswire/ -- December 14-15, 2024, at Saigon Riverside Park, Hipfest 2024 festival - organized by the Viet Nam Union of Friendship Organizations, and Enter CEC Company Limited, will officially take place,...
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 9, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263...
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced...
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...